Maxygen Overview and Company Structure

Maxygen is a biotech company that was founded in 1999 by a team of researchers from the University of Colorado.

The company's initial focus was on developing novel therapeutics for cancer and other diseases using a proprietary technology called the "MAX" system.

Maxygen's MAX system is a platform for generating and screening large numbers of genetic variants to identify new targets for therapy.

Maxygen's research and development efforts were led by a team of experienced scientists and clinicians, including Dr. John Maraganore, the company's CEO and President.

Maxygen had a clear leadership structure in place, with a Chief Scientific Officer named Robert Whalen and a Vice-President of Research named James English. They were key figures in the company's research efforts.

Tassos Gianakakos, a former Director of Business Development, played a significant role in the company's business development. His experience would have been valuable in driving the company's growth.

Here is a brief rundown of the leadership team:

Maxygen has raised funding over 2 rounds. Its first funding round was on Aug 01, 2008.

One of its latest funding rounds was a Grant (prize money) round on Sep 24, 2008, securing $850K. Presidio Partners and Startup Sauna were involved in this round.

Only one investor participated in Maxygen's latest funding round.

Presidio Partners and Startup Sauna are two of Maxygen's institutional investors.

Maxygen's founders and board of directors are worth noting. Willem Pim Stemmer is the founder of Maxygen.

Russell Howard is not only the CEO of Maxygen but also the founder of another company, making him a notable figure in the leadership of Maxygen.

Here's a brief rundown of Maxygen's leadership:

Maxygen Inc. focused its research and development efforts on creating innovative treatments. The company's clinical programs included a novel G-CSF for chemotherapy-induced neutropenia, which entered clinical trials in 2006.

Maxygen also explored the treatment of rheumatoid arthritis and other autoimmune diseases with a preclinical program, MAXY-4, to develop a novel CTLA4-Ig therapeutic. This program aimed to leverage the company's proprietary technologies for creating genetic diversity.

Maxygen's Molecular Breeding directed evolution platform allowed for the generation of millions of variant genes and proteins, which were then screened for potential commercial interest. This process mimicked the natural process of evolution, as documented in a 1998 Nature letter and numerous scientific publications and patents.

Maxygen Inc had a strong focus on clinical programs, which aimed to develop innovative treatments for various diseases.

A novel G-CSF was one of the clinical programs, designed to treat chemotherapy-induced neutropenia, and it entered clinical trials in 2006.

Maxygen also had a preclinical program, MAXY-4, to develop a novel CTLA4-Ig therapeutic for the treatment of rheumatoid arthritis and other autoimmune diseases.

Maxygen Inc. was established to commercially exploit its proprietary recombination-based technologies for creating genetic diversity, known as its Molecular Breeding directed evolution platform.

These technologies allow the generation of millions of variant genes and proteins, which then can be screened to identify those with potential commercial interest.

This laboratory process mimics the powerful natural process of evolution, making it a revolutionary tool in the field of genetic research.

The success of Maxygen's technology was documented in numerous scientific publications and patents, including a 1998 Nature letter.

Maxygen had a defined corporate structure, with key roles held by Robert Whalen as Chief Scientific Officer and James English as Vice-President of Research.

The company had a clear leadership hierarchy, with these two positions playing important roles in the research and scientific aspects of the business.

Tassos Gianakakos previously served as Director of Business Development, indicating that the company had a dedicated team for business development and growth.

Here are the key roles in Maxygen's corporate structure:

Maxygen was founded in 1997 by Dr. Alejandro Zaffaroni and three co-founders, with Dr. Zaffaroni having previously founded multiple companies.

The company was initially focused on engineering interferons and was based in Santa Clara in 1998. By 2000, its headquarters had moved to Redwood City.

In 2000, Maxygen went public, along with two of its direct competitors: Diversa, Applied Molecular Evolution, and Genencor International. Another company, Enchira Biotechnology, was also a direct competitor.

The firm had also licensed a compound to H. Lundbeck by 2000 and applied its technology against subtililsin by the same year.

Maxygen established Codexis in 2002 to focus on enzyme/chemical applications and MaxyAg to focus on agricultural applications, which was later renamed Verdia Inc. and sold to DuPont in 2004 for $64 million.

Recommended read: Focus Financial Partners

Avidia was established in 2003 to develop protein subunits as commercial products, including therapeutics, and was purchased by Amgen in 2006 for $290 million.

The company sold its MAXY-VII candidate drug to Bayer HealthCare in 2008 and formed a joint venture with Astellas in 2009, called Perseid Therapeutics, in which Maxygen retained majority ownership.

By 2011, Astellas had exercised an option to fully acquire Perseid and its sole candidate drug, MAXY-4, which became ASP2408 under Astellas, a CTLA-4-immunoglobulin fusion protein therapeutic.

Related reading: Meyer Brothers Drug Company